Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d

被引:70
作者
Bower, JF
Yang, XZ
Sodroski, J
Ross, TM
机构
[1] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15261 USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Div Aids, Boston, MA 02115 USA
关键词
D O I
10.1128/JVI.78.9.4710-4719.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
DNA vaccines expressing the envelope (Env) of human immunodeficiency virus type I (HIV-1) have been relatively ineffective at generating high-titer, long-lasting immune responses. Oligomeric or trimeric (gp140) forms of Env that more closely mimic the native proteins on the virion are often more effective immunogens than monomeric (gp120) envelopes. In this study, several forms of Env constructed from the HIV-1 isolate YU-2 (HIV-1(YU-2)) were tested for their immunogenic potential: a trimeric form of uncleaved (-) Env stabilized with a synthetic trimer motif isolated from the fibritin (IT) protein of the T4 bacteriophage, sgp140(YU-2)(-/FT), was compared to sgp140(YU)-2(-) without a synthetic trimerization domain, as well as to monomeric gp120(YU)-2. DNA plasmids were constructed to express Env alone or fused to various copies of murine C3d (mCM). BALB/c mice were vaccinated (day 1 and week 4) with DNA expressing a codon-optimized envelope gene insert, alone or fused to mC3d. Mice were subsequently boosted (week 8) with the DNA or recombinant Env protein. All mice had high anti-Env antibody titers regardless of the use of mC3d. Sera from mice vaccinated with DNA expressing non-C3d-fused trimers elicited neutralizing antibodies against homologous HIV-1(YU-2) virus infection in vitro. In contrast, sera from mice inoculated with DNA expressing Env-C3d protein trimers elicited antibody that neutralized both homologous HIV-1(YU-2) and heterologous RIV-1(ADA), albeit at low titers. Therefore, DNA vaccines expressing trimeric envelopes coupled to mC3d, expressed in vivo from codon-optimized sequences, elicit low titers of neutralizing antibodies against primary isolates of HIV-1.
引用
收藏
页码:4710 / 4719
页数:10
相关论文
共 69 条
  • [31] C3d enhancement of neutralizing, antibodies to measles hemagglutinin
    Green, TD
    Newton, BR
    Rota, PA
    Xu, Y
    Robinson, HL
    Ross, TM
    [J]. VACCINE, 2001, 20 (1-2) : 242 - 248
  • [32] Codon usage limitation in the expression of HIV-1 envelope glycoprotein
    Haas, J
    Park, EC
    Seed, B
    [J]. CURRENT BIOLOGY, 1996, 6 (03) : 315 - 324
  • [33] Particle-mediated nucleic acid immunization
    Haynes, JR
    McCabe, DE
    Swain, WF
    Widera, G
    Fuller, JT
    [J]. JOURNAL OF BIOTECHNOLOGY, 1996, 44 (1-3) : 37 - 42
  • [34] Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: Implications for membrane association and assembly
    Hill, CP
    Worthylake, D
    Bancroft, DP
    Christensen, AM
    Sundquist, WI
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (07) : 3099 - 3104
  • [35] CROSS-NEUTRALIZING ANTIBODIES IN RABBITS IMMUNIZED WITH HIV-1 GP160 PURIFIED FROM SIMIAN CELLS INFECTED WITH A RECOMBINANT VACCINIA VIRUS
    KLANIECKI, J
    DYKERS, T
    TRAVIS, B
    SCHMITT, R
    WAIN, M
    WATSON, A
    SRIDHAR, P
    MCCLURE, J
    MOREIN, B
    ULRICH, JT
    HU, SL
    LEWIS, J
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (10) : 791 - 798
  • [36] CO-LIGATION OF MOUSE COMPLEMENT RECEPTOR-1 AND RECEPTOR-2 WITH SURFACE IGM RESCUES SPLENIC B-CELLS AND WEHT-231 CELLS FROM ANTISURFACE IGM-INDUCED APOPTOSIS
    KOZONO, Y
    DUKE, RC
    SCHLEICHER, MS
    HOLERS, VM
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (04) : 1013 - 1017
  • [37] LIU F, IN PRESS VACCINE
  • [38] Liu MA, 1998, ADV EXP MED BIOL, V452, P187
  • [39] Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins
    Mitchell, JA
    Green, TD
    Bright, RA
    Ross, TM
    [J]. VACCINE, 2003, 21 (9-10) : 902 - 914
  • [40] Mongini PKA, 1997, J IMMUNOL, V159, P3782